Sanofi Genzyme

Trials for CAD


Currently, they are 2 clinical trials being offered from Sanofi Genzyme.

 For more information on the clinical trials being offered please go to::

BIVV009 A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants with Primary Cold Agglutinin Disease Without A Recent History of Blood transfusion. Phase 3 Trial Identifier: NCT03347422 (Cadenza Study)

Search Cold Agglutinin Disease  Recruiting Estimated Completion Date December 2021 


The CAD Cadenza Study is now recruiting adults ages 18 and older with primary cold agglutinin disease (CAD). The purpose of the CAD Study is to determine the safety and effectiveness of an investigational medication when compared to placebo for primary CAD. Individuals will be evaluated to determine their eligibility to participate. The investigational medication, study-related medical exams, and study-related laboratory tests will be provided to participants at no cost.  

BIVV020 A Safety and Tolerability Study of BIVV020 in Adults with Cold Agglutinin Disease. Phase 1 Trial Identifier: NCT04269551  Search Cold Agglutinin Disease Autoimmune Hemolytic Anemia  Recruiting Estimated Completion Date September 2021  


Certain links within this site connect to other websites maintained by third parties over whom CADF has no control. CADF makes no representations as to the accuracy or any other aspect of information contained in other websites.

Providing these links does not imply any endorsement, non-endorsement, support or commercial gain by CADF.